161 related articles for article (PubMed ID: 30083976)
41. Peptidyl inhibitors of shaker-type Kv1 channels elicit twitches in guinea pig ileum by blocking kv1.1 at enteric nervous system and enhancing acetylcholine release.
Suarez-Kurtz G; Vianna-Jorge R; Pereira BF; Garcia ML; Kaczorowski GJ
J Pharmacol Exp Ther; 1999 Jun; 289(3):1517-22. PubMed ID: 10336547
[TBL] [Abstract][Full Text] [Related]
42. ImKTx1, a new Kv1.3 channel blocker with a unique primary structure.
Chen Z; Hu Y; Han S; Yin S; He Y; Wu Y; Cao Z; Li W
J Biochem Mol Toxicol; 2011; 25(4):244-51. PubMed ID: 21308893
[TBL] [Abstract][Full Text] [Related]
43. Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes.
Gurrola GB; Hernández-López RA; Rodríguez de la Vega RC; Varga Z; Batista CV; Salas-Castillo SP; Panyi G; del Río-Portilla F; Possani LD
Biochemistry; 2012 May; 51(19):4049-61. PubMed ID: 22540187
[TBL] [Abstract][Full Text] [Related]
44. Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels.
Bartok A; Toth A; Somodi S; Szanto TG; Hajdu P; Panyi G; Varga Z
Toxicon; 2014 Sep; 87():6-16. PubMed ID: 24878374
[TBL] [Abstract][Full Text] [Related]
45. A potent potassium channel blocker from Mesobuthus eupeus scorpion venom.
Gao B; Peigneur S; Tytgat J; Zhu S
Biochimie; 2010 Dec; 92(12):1847-53. PubMed ID: 20713119
[TBL] [Abstract][Full Text] [Related]
46. Molecular dynamics of Kv1.3 ion channel and structural basis of its inhibition by scorpion toxin-OSK1 derivatives.
Bhuyan R; Seal A
Biophys Chem; 2015; 203-204():1-11. PubMed ID: 26001067
[TBL] [Abstract][Full Text] [Related]
47. Human immunodeficiency virus protein Tat induces oligodendrocyte injury by enhancing outward K
Liu H; Liu J; Xu E; Tu G; Guo M; Liang S; Xiong H
Neurobiol Dis; 2017 Jan; 97(Pt A):1-10. PubMed ID: 27816768
[TBL] [Abstract][Full Text] [Related]
48. The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies.
Pérez-Verdaguer M; Capera J; Serrano-Novillo C; Estadella I; Sastre D; Felipe A
Expert Opin Ther Targets; 2016; 20(5):577-91. PubMed ID: 26634786
[TBL] [Abstract][Full Text] [Related]
49. Discovery of three toxin peptides with Kv1.3 channel and IL-2 cytokine-inhibiting activities from Non-Buthidae scorpions, Chaerilus tricostatus and Chaerilus tryznai.
Ding L; Chen J; Hao J; Zhang J; Huang X; Hu F; Wu Z; Liu Y; Li W; Cao Z; Wu Y; Li J; Li S; Liu H; Wu W; Chen Z
Peptides; 2017 May; 91():13-19. PubMed ID: 28300672
[TBL] [Abstract][Full Text] [Related]
50. Expression and characterization of a novel scorpine-like peptide Ev37, from the scorpion Euscorpiops validus.
Feng J; Yu C; Wang M; Li Z; Wu Y; Cao Z; Li W; He X; Han S
Protein Expr Purif; 2013 Mar; 88(1):127-33. PubMed ID: 23262394
[TBL] [Abstract][Full Text] [Related]
51. Characterization of a new Kv1.3 channel-specific blocker, J123, from the scorpion Buthus martensii Karsch.
Shijin Y; Hong Y; Yibao M; Zongyun C; Han S; Yingliang W; Zhijian C; Wenxin L
Peptides; 2008 Sep; 29(9):1514-20. PubMed ID: 18571286
[TBL] [Abstract][Full Text] [Related]
52. Modulation of voltage-dependent and inward rectifier potassium channels by 15-epi-lipoxin-A4 in activated murine macrophages: implications in innate immunity.
Moreno C; Prieto P; Macías Á; Pimentel-Santillana M; de la Cruz A; Través PG; Boscá L; Valenzuela C
J Immunol; 2013 Dec; 191(12):6136-46. PubMed ID: 24249731
[TBL] [Abstract][Full Text] [Related]
53. Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation.
Liebau S; Pröpper C; Böckers T; Lehmann-Horn F; Storch A; Grissmer S; Wittekindt OH
J Neurochem; 2006 Oct; 99(2):426-37. PubMed ID: 17029597
[TBL] [Abstract][Full Text] [Related]
54. Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1[R14A], a K
Reddiar SB; Jin L; Wai DCC; Csoti A; Panyi G; Norton RS; Nicolazzo JA
Toxicon; 2021 May; 195():29-36. PubMed ID: 33689790
[TBL] [Abstract][Full Text] [Related]
55. Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease.
Valverde P; Kawai T; Taubman MA
J Dent Res; 2005 Jun; 84(6):488-99. PubMed ID: 15914584
[TBL] [Abstract][Full Text] [Related]
56. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
57. Potassium channel changes of peripheral blood T-lymphocytes from Kazakh hypertensive patients in Northwest China and the inhibition effect towards potassium channels by telmisartan.
Zhang Q; Gou F; Zhang Y; He Y; He J; Peng L; Cheng L; Yuan Q; Zhang G; Huang S
Kardiol Pol; 2016; 74(5):476-488. PubMed ID: 26502942
[TBL] [Abstract][Full Text] [Related]
58. Mapping the Interaction Anatomy of BmP02 on Kv1.3 Channel.
Wu B; Wu BF; Feng YJ; Tao J; Ji YH
Sci Rep; 2016 Jul; 6():29431. PubMed ID: 27403813
[TBL] [Abstract][Full Text] [Related]
59. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3.
Felix JP; Bugianesi RM; Schmalhofer WA; Borris R; Goetz MA; Hensens OD; Bao JM; Kayser F; Parsons WH; Rupprecht K; Garcia ML; Kaczorowski GJ; Slaughter RS
Biochemistry; 1999 Apr; 38(16):4922-30. PubMed ID: 10213593
[TBL] [Abstract][Full Text] [Related]
60. Characterization of the outer pore region of the apamin-sensitive Ca2+-activated K+ channel rSK2.
Jäger H; Grissmer S
Toxicon; 2004 Jun; 43(8):951-60. PubMed ID: 15208028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
